Abbott Laboratories (ABT) Accounts Payables (2009 - 2026)

Abbott Laboratories' Accounts Payables history runs 18 years deep, the most recent figure standing at $4.7 billion for Q1 2026.

• In Q1 2026, Accounts Payables rose 11.03% year-over-year to $4.7 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 11.03% YoY), while the FY2025 annual figure was $4.2 billion, up 1.07% from the prior year.
• Accounts Payables came in at $4.7 billion for Q1 2026 at Abbott Laboratories, up from $4.2 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.8 billion in Q1 2022 to a low of $4.0 billion in Q3 2023.
• A 5-year average of $4.3 billion and a median of $4.2 billion in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables gained 16.99% in 2022 and decreased 12.4% in 2023, its largest moves.
• Abbott Laboratories' Accounts Payables stood at $4.6 billion in 2022, then dropped by 6.77% to $4.3 billion in 2023, then slipped by 2.33% to $4.2 billion in 2024, then grew by 1.07% to $4.2 billion in 2025, then rose by 10.35% to $4.7 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.7 billion, $4.2 billion, and $4.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison